Strata Skin Sciences Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Strata Skin Sciences Inc has an operating margin of -27.6%, meaning the company retains $-28 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -25.8% the prior year.
Strata Skin Sciences Inc's revenue grew a modest 0.6% year-over-year to $33.6M. This slow but positive growth earns a score of 30/100.
Strata Skin Sciences Inc has elevated debt relative to equity (D/E of 3.06), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Strata Skin Sciences Inc's current ratio of 1.24 indicates adequate short-term liquidity, earning a score of 30/100. The company can meet its near-term obligations, though with limited headroom.
While Strata Skin Sciences Inc generated $188K in operating cash flow, capex of $1.6M consumed most of it, leaving -$1.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Strata Skin Sciences Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Strata Skin Sciences Inc generates $-0.02 in operating cash flow ($188K OCF vs -$10.1M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Strata Skin Sciences Inc earns $-4.4 in operating income for every $1 of interest expense (-$9.3M vs $2.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Strata Skin Sciences Inc (SSKN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Strata Skin Sciences Inc generated $33.6M in revenue in fiscal year 2024. This represents an increase of 0.6% from the prior year.
Strata Skin Sciences Inc's EBITDA was -$4.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 40.5% from the prior year.
Strata Skin Sciences Inc generated -$1.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 73.9% from the prior year.
Strata Skin Sciences Inc reported -$10.1M in net income in fiscal year 2024. This represents an increase of 6.9% from the prior year.
Strata Skin Sciences Inc earned $-2.65 per diluted share (EPS) in fiscal year 2024. This represents an increase of 14.5% from the prior year.
Strata Skin Sciences Inc held $7.3M in cash against $15.2M in long-term debt as of fiscal year 2024.
Strata Skin Sciences Inc had 4M shares outstanding in fiscal year 2024. This represents an increase of 19.0% from the prior year.
Strata Skin Sciences Inc's gross margin was 56.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 1.5 percentage points from the prior year.
Strata Skin Sciences Inc's operating margin was -27.6% in fiscal year 2024, reflecting core business profitability. This is down 1.8 percentage points from the prior year.
Strata Skin Sciences Inc's net profit margin was -30.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 2.4 percentage points from the prior year.
Strata Skin Sciences Inc invested $883K in research and development in fiscal year 2024. This represents a decrease of 33.0% from the prior year.
Strata Skin Sciences Inc invested $1.6M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 67.4% from the prior year.
SSKN Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.9M-9.6% | $7.7M+12.5% | $6.8M-28.9% | $9.6M+13.5% | $8.4M+24.9% | $6.8M-22.3% | $8.7M-1.8% | $8.9M |
| Cost of Revenue | $2.7M-18.2% | $3.4M+6.1% | $3.2M-17.5% | $3.8M+11.0% | $3.5M-5.9% | $3.7M-5.5% | $3.9M-0.3% | $3.9M |
| Gross Profit | $4.2M-2.8% | $4.3M+18.1% | $3.6M-36.4% | $5.7M+15.3% | $5.0M+61.6% | $3.1M-35.8% | $4.8M-3.1% | $5.0M |
| R&D Expenses | $172K+100.0% | $86K-10.4% | $96K-52.0% | $200K+0.5% | $199K-17.4% | $241K-36.6% | $380K+53.2% | $248K |
| SG&A Expenses | $2.7M-11.0% | $3.0M+32.4% | $2.3M-4.3% | $2.4M+7.4% | $2.2M-18.7% | $2.7M-3.9% | $2.8M+23.4% | $2.3M |
| Operating Income | -$1.2M+49.2% | -$2.3M-35.5% | -$1.7M+60.2% | -$4.3M-796.4% | -$478K+83.4% | -$2.9M+16.1% | -$3.4M-459.5% | -$615K |
| Interest Expense | $498K+1.4% | $491K+1.0% | $486K-5.6% | $515K-3.0% | $531K+1.3% | $524K-0.8% | $528K0.0% | $528K |
| Income Tax | $0 | $0 | $0+100.0% | -$170K | $0 | $0+100.0% | -$92K | $0 |
| Net Income | -$1.6M+37.0% | -$2.6M-21.3% | -$2.1M+53.4% | -$4.6M-4905.5% | -$91K+97.3% | -$3.4M+11.3% | -$3.8M-260.3% | -$1.1M |
| EPS (Diluted) | $-0.36+41.9% | $-0.62-21.6% | $-0.51+74.6% | $-2.01-6600.0% | $-0.03 | $-0.10 | $-1.82 | $-0.30 |
SSKN Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $30.7M+4.2% | $29.5M-10.7% | $33.0M-5.4% | $34.9M-9.9% | $38.8M-1.2% | $39.2M-6.6% | $42.0M-11.0% | $47.2M |
| Current Assets | $14.3M+3.6% | $13.8M-13.2% | $15.9M-4.3% | $16.6M+20.0% | $13.8M+4.4% | $13.2M-14.8% | $15.5M-21.2% | $19.7M |
| Cash & Equivalents | $7.1M+18.6% | $6.0M-8.4% | $6.5M-10.3% | $7.3M+32.4% | $5.5M+4.7% | $5.2M-22.8% | $6.8M-4.9% | $7.1M |
| Inventory | $3.1M-5.5% | $3.2M+21.7% | $2.7M+18.4% | $2.2M-16.6% | $2.7M-0.1% | $2.7M+0.8% | $2.7M-56.4% | $6.1M |
| Accounts Receivable | $3.5M-12.9% | $4.0M-19.7% | $5.0M-4.7% | $5.3M+32.0% | $4.0M+9.6% | $3.6M-18.2% | $4.4M-7.5% | $4.8M |
| Goodwill | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M-74.9% | $5.7M0.0% | $5.7M-12.6% | $6.5M-25.9% | $8.8M |
| Total Liabilities | $29.4M+1.5% | $29.0M-3.6% | $30.1M+0.3% | $30.0M+2.4% | $29.3M-1.8% | $29.8M+1.6% | $29.3M-5.4% | $31.0M |
| Current Liabilities | $15.0M+19.8% | $12.6M-7.7% | $13.6M+1.5% | $13.4M+18.5% | $11.3M-3.9% | $11.8M-3.4% | $12.2M+1.2% | $12.0M |
| Long-Term Debt | $13.4M-12.0% | $15.3M+0.3% | $15.2M+0.3% | $15.2M+0.5% | $15.1M+0.3% | $15.1M+0.2% | $15.0M+0.2% | $15.0M |
| Total Equity | $1.3M+147.0% | $532K-82.1% | $3.0M-40.1% | $5.0M-47.7% | $9.5M+0.8% | $9.4M-25.6% | $12.7M-21.6% | $16.2M |
| Retained Earnings | -$254.5M-0.6% | -$252.8M-1.0% | -$250.3M-0.9% | -$248.1M-2.7% | -$241.5M0.0% | -$241.4M-1.4% | -$238.1M-1.6% | -$234.3M |
SSKN Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$64K+96.7% | -$1.9M-252.9% | -$550K-178.2% | $703K+19.0% | $591K+173.5% | -$804K-158.6% | $1.4M+167.9% | -$2.0M |
| Capital Expenditures | $1.0M+1768.9% | -$61K-130.7% | $199K-60.5% | $504K+46.1% | $345K-52.4% | $725K-57.8% | $1.7M+985.6% | -$194K |
| Free Cash Flow | -$1.1M+46.0% | -$2.0M-167.3% | -$749K-476.4% | $199K-19.1% | $246K+116.1% | -$1.5M-340.6% | -$347K+84.3% | -$2.2M |
| Investing Cash Flow | -$1.0M-1768.9% | $61K+130.7% | -$199K+60.5% | -$504K-46.1% | -$345K+52.4% | -$725K+57.8% | -$1.7M-985.6% | $194K |
| Financing Cash Flow | $2.2M | $0 | $0 | $0 | $0+100.0% | -$18K | $0+100.0% | -$104K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SSKN Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.4%+4.2pp | 56.2%+2.6pp | 53.5%-6.4pp | 59.9%+0.9pp | 59.0%+13.4pp | 45.6%-9.6pp | 55.3%-0.7pp | 56.0% |
| Operating Margin | -16.9%+13.2pp | -30.1%-5.1pp | -25.0%+19.7pp | -44.8%-39.1pp | -5.7%+37.1pp | -42.8%-3.1pp | -39.6%-32.6pp | -7.0% |
| Net Margin | -23.4%+10.2pp | -33.6%-2.5pp | -31.1%+16.4pp | -47.6%-46.5pp | -1.1%+48.8pp | -49.8%-6.2pp | -43.7%-31.8pp | -11.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -5.3%+3.5pp | -8.7%-2.3pp | -6.4%+6.6pp | -13.0%-12.8pp | -0.2%+8.3pp | -8.6%+0.5pp | -9.0%-6.8pp | -2.2% |
| Current Ratio | 0.95-0.1 | 1.10-0.1 | 1.17-0.1 | 1.24+0.0 | 1.22+0.1 | 1.13-0.2 | 1.28-0.4 | 1.64 |
| Debt-to-Equity | 10.22-18.5 | 28.70+23.6 | 5.11+2.1 | 3.06+1.5 | 1.590.0 | 1.60+0.4 | 1.19+0.3 | 0.93 |
| FCF Margin | -15.6%+10.5pp | -26.1%-15.1pp | -11.0%-13.1pp | 2.1%-0.8pp | 2.9%+25.6pp | -22.6%-18.6pp | -4.0%+21.0pp | -25.0% |
Similar Companies
Frequently Asked Questions
What is Strata Skin Sciences Inc's annual revenue?
Strata Skin Sciences Inc (SSKN) reported $33.6M in total revenue for fiscal year 2024. This represents a 0.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Strata Skin Sciences Inc's revenue growing?
Strata Skin Sciences Inc (SSKN) revenue grew by 0.6% year-over-year, from $33.4M to $33.6M in fiscal year 2024.
Is Strata Skin Sciences Inc profitable?
No, Strata Skin Sciences Inc (SSKN) reported a net income of -$10.1M in fiscal year 2024, with a net profit margin of -30.0%.
What is Strata Skin Sciences Inc's earnings per share (EPS)?
Strata Skin Sciences Inc (SSKN) reported diluted earnings per share of $-2.65 for fiscal year 2024. This represents a 14.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Strata Skin Sciences Inc's EBITDA?
Strata Skin Sciences Inc (SSKN) had EBITDA of -$4.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Strata Skin Sciences Inc have?
As of fiscal year 2024, Strata Skin Sciences Inc (SSKN) had $7.3M in cash and equivalents against $15.2M in long-term debt.
What is Strata Skin Sciences Inc's gross margin?
Strata Skin Sciences Inc (SSKN) had a gross margin of 56.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Strata Skin Sciences Inc's operating margin?
Strata Skin Sciences Inc (SSKN) had an operating margin of -27.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Strata Skin Sciences Inc's net profit margin?
Strata Skin Sciences Inc (SSKN) had a net profit margin of -30.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Strata Skin Sciences Inc's free cash flow?
Strata Skin Sciences Inc (SSKN) generated -$1.4M in free cash flow during fiscal year 2024. This represents a 73.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Strata Skin Sciences Inc's operating cash flow?
Strata Skin Sciences Inc (SSKN) generated $188K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Strata Skin Sciences Inc's total assets?
Strata Skin Sciences Inc (SSKN) had $34.9M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Strata Skin Sciences Inc's capital expenditures?
Strata Skin Sciences Inc (SSKN) invested $1.6M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Strata Skin Sciences Inc spend on research and development?
Strata Skin Sciences Inc (SSKN) invested $883K in research and development during fiscal year 2024.
How many shares does Strata Skin Sciences Inc have outstanding?
Strata Skin Sciences Inc (SSKN) had 4M shares outstanding as of fiscal year 2024.
What is Strata Skin Sciences Inc's current ratio?
Strata Skin Sciences Inc (SSKN) had a current ratio of 1.24 as of fiscal year 2024, which is considered adequate.
What is Strata Skin Sciences Inc's debt-to-equity ratio?
Strata Skin Sciences Inc (SSKN) had a debt-to-equity ratio of 3.06 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Strata Skin Sciences Inc's return on assets (ROA)?
Strata Skin Sciences Inc (SSKN) had a return on assets of -28.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Strata Skin Sciences Inc's Piotroski F-Score?
Strata Skin Sciences Inc (SSKN) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Strata Skin Sciences Inc's earnings high quality?
Strata Skin Sciences Inc (SSKN) has an earnings quality ratio of -0.02x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Strata Skin Sciences Inc cover its interest payments?
Strata Skin Sciences Inc (SSKN) has an interest coverage ratio of -4.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Strata Skin Sciences Inc?
Strata Skin Sciences Inc (SSKN) scores 12 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.